Shots:
- 4DMT reported 2yr. data from the P-IIb (PRISM) trial evaluating intravitreal 4D-150 at 3E10 vg/eye (n=30) & 1E10 vg/eye (n=15) in 45 pts with wet age-related macular degeneration
- P-IIb subgroup incl. 15 recently diagnosed pts treated with 3E10 vg/eye, which was also selected for the P-III (4FRONT) trials, with the 2-year Phase 2b data presented at ASRS
- Through 2yrs., 4D-150 maintained BCVA & CST control while significantly reducing treatment burden by 78% overall & 87% in recently diagnosed pts vs projected on-label aflibercept dosing, with a sustained dose response favoring the P-III dose
Ref: Globenewswire | Image: 4DMT | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us atconnect@pharmashots.com
